Gregor H.
- Country
- Austria
- Department
- Medical office
Research Overview
- Efficacy and Safety of Olaparib as Adjuvant Therapy in Germline BRCA1/2 Mutated High-Risk HER2-Negative Primary Breast Cancer: A Phase III Randomized Study
- Phase III Randomized Trial of Palbociclib Plus Endocrine Therapy Versus Endocrine Therapy Alone in HR+/HER2- Early Breast Cancer
- CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence
Data & Insights
Has run more than one trial at 198 of 440 partner sites.
Specializations
Breast Cancer Recurrence Prevention
Gregor Huber is involved in clinical research focused on breast cancer with an emphasis on reducing recurrence in patients with ER+/HER2- early breast cancer. His trial portfolio reflects interest in adjuvant treatment strategies designed to improve long-term disease control after initial therapy.
- Endocrine therapy for recurrence prevention
- Adjuvant treatment in early-stage disease
- Hormone receptor-positive / HER2-negative breast cancer
His research activity in this area is centered on clinical approaches that aim to strengthen standard post-operative management for patients at risk of disease return.
Hormone-Receptor-Positive Early Breast Cancer
His work includes studies in HR+/HER2- invasive early breast cancer, with attention to treatment intensification beyond endocrine therapy alone. This area is especially relevant to patients requiring extended systemic management after primary treatment.
- Adjuvant endocrine therapy
- Invasive disease-free survival
- Early breast cancer management
The clinical focus here is on improving outcomes in localized disease through therapies tailored to the biology of hormone receptor-positive tumors.
Targeted Endocrine-Based Therapy
Gregor Huber is also engaged in research on newer endocrine-based therapies for ER+/HER2- breast cancer, including agents intended to extend the benefit of standard hormonal treatment. These studies address therapeutic options for preventing relapse in the adjuvant setting.
- Selective estrogen receptor modulation
- Extended adjuvant therapy
- Recurrence reduction
This research domain connects conventional endocrine treatment with newer targeted strategies in early breast cancer care.
PARP Inhibition in High-Risk Disease
His clinical trial involvement includes olaparib in germline BRCA-mutated high-risk primary breast cancer, highlighting interest in DNA repair–targeted therapy. This area reflects attention to patients whose tumor biology supports precision-based adjuvant treatment.
- BRCA-mutated breast cancer
- PARP inhibitor therapy
- Invasive disease-free survival
The therapeutic emphasis is on integrating molecularly directed treatment into early breast cancer management for patients with higher relapse risk.
CDK4/6 Inhibition in the Adjuvant Setting
Gregor Huber’s trial activity also includes palbociclib and abemaciclib in combination with endocrine therapy for HR+/HER2- early breast cancer. This area focuses on cell-cycle inhibition as part of adjuvant treatment strategies aimed at improving disease control.
- CDK4/6 inhibitor treatment
- Adjuvant combination therapy
- Breast cancer recurrence prevention
His research involvement supports the development of combination approaches that extend standard endocrine therapy in early-stage breast cancer.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.